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Abstract
Background: The incidence of hepatocellular carcinoma is increasing in many countries. The estimated
number of new cases annually is over 500,000, and the yearly incidence comprises between 2.5 and 7% of
patients with liver cirrhosis. The incidence varies between different geographic areas, being higher in
developing areas; males are predominantly affected, with a 2:3 male/female ratio
Methods:  Experiments were designed to examine the effect of N-Nitrosodiethylamine (NDEA) as
cancer-inducer compound and to confirm the preventive effect of the flavonoid quercetin on
hepatocellular carcinoma in rats. Briefly, thirty six male albino rats of Wistar strain were divided into 3
groups: the 1st group was administered NDEA alone (NDEA-treated), the 2nd group was treated
simultaneously with NDEA and quercetin (NDEA+Q) and the 3rd group was used as control (CON).
Randomly amplified polymorphic DNA polymerase chain reaction (RAPD-PCR) as well as p53-specifi PCR
assays were employed to determine genomic difference between treated, and control animals. Histological
confirmation as well as oxidant/antioxidant status of the liver tissue was done.
Results: RAPD analysis of liver samples generated 8 monomorphic bands and 22 polymorphic bands in a
total of 30-banded RAPD patterns. Cluster analysis and statistical analyses of RAPD data resulted in
grouping control and NDEA+Q samples in the same group with 80% similarity cut-off value. NDEA-
treated samples were clustered in a separate group. Specific PCR assay for polymorphism of P53 gene
revealed a uniform pattern of allele separation in both control and NDEA+Q samples. Quercetin
anticancer effect was exhibited in significant decrease of oxidative stress and significant decrease of
antioxidant activity. Histopathological studies showed normal liver histology of the NDEA+Q samples.
Meanwhile, several cancer-induced features were clearly observable in NDEA-treated samples.
Conclusion: This paper demonstrated that preventive effect of quercetin on hepatocarcinoma in rats by
RAPD-PCR, tracing the effect on p53 gene and by histopathological evidence. Hereby, it was proved that
quercetin exerted its preventive effect via decreased oxidative stress and decreased antioxidant activity.
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Background
The incidence of hepatocellular carcinoma is increasing in
many countries. The estimated number of new cases
annually is over 500,000, and the yearly incidence com-
prises between 2.5 and 7% of patients with liver cirrhosis.
The incidence varies between different geographic areas,
being higher in developing areas; males are predomi-
nantly affected, with a 2:3 male/female ratio [1]. Malig-
nant transformation of cell is due to the progressive
accumulation of mutations, stable nonmutational (epige-
netic) alterations in gene expression and/or gene product
(protein) function [2]. Chemical carcinogens could be
classified as genotoxic and nongenotoxic [3]. Although
nongenotoxic carcinogen is not mutagenic, it may stimu-
late cell proliferation, inhibit apoptosis, increase inflam-
mation, and/or induce stable or transient epigenetic
changes in critical genes of terminally proliferating cells
[3]. Nitrosamines are known as precarcinogens capable of
inducing tumors in different animal species and are sus-
pected of being involved in some human tumors [4]. N-
Nitrosodiethylamine (NDEA), which is present in the
environment [5] and in tobacco smoke, and is also syn-
thesized endogenously [6], induces tumors in all species
tested so far [7]. In contrast, Andrzejewski et al. [8] postu-
lated that NDEA is epigenetic.
The antitumor effects of plant flavonoids have been
reported to induce cell growth inhibition and apoptosis in
a variety of cancer cells [9]. Quercetin, a ubiquitous bioac-
tive flavonoid, can inhibit the proliferation of cancer cells
[10,11]. It has been shown that quercetin treatment
caused cell cycle arrests such as G2/M arrest or G1 arrest in
different cell types [10,12]. Moreover, quercetin-mediated
apoptosis may result from the induction of stress proteins,
disruption of microtubules and mitochondrial, release of
cytochrome c, and activation of caspases [11,13,14]. Li et
al. [15] suggested that alpha methylacyl-coenzyme A race-
mase (AMACR) staining may serve as a useful marker for
the differential diagnosis of well-differentiated HCC from
HCA. Increased AMACR expression and its association
with tumor venous invasion suggest that AMACR may
play a role in HCC development and progression.
Lipid peroxidation, initiated in the presence of hydroxy
radicals resulting in the production of malondialdehyde
(MDA), directly produces oxidative stress [16]. Glutath-
ione (GSH) is a key player in reduction processes in the
cell. It also plays a role in reduction of NTPs to dNTPs and
in detoxification of endogenous and exogenous com-
pounds, serves as a cofactor for various enzymes, stores
and transports cysteine, and may be involved in cell cycle
regulation and thermotolerance [17]. Glutathione reduct-
ase (GR) is a gene encoding for an enzyme which reduces
glutathione disulfide (GSSG) to the sulfhydryl form GSH,
which is an important cellular antioxidant [18,19]. Glu-
tathione peroxidase (GPX) is a general name of enzyme
family with peroxidase activity whose main biological
role is to protect the organism from oxidative damage. The
biochemical function of glutathione peroxidase is to
reduce lipid hydroperoxides to their corresponding alco-
hols and to reduce free hydrogen peroxide to water
[18,19].
The main objectives of the present work were to examine
the effect of NDEA as cancer-inducer compound and to
confirm and throw light on the preventive effect of the fla-
vonoid quercetin on hepatocellular carcinoma in rats.
However, these issues are still debatable.
Methods
Animals and drugs
A total of 36 male albino rats of Wistar strain (170–200 g
each), obtained from the central animal house of Faculty
of Pharmacy, Cairo University, Cairo, Egypt were used in
the present study. Animals were kept in groups at constant
nutritional and highly controlled conditions: 23 ± 1°C
temperature, 60 ± 10% RH and 12 L: 12 D photoperiod
throughout the experimental period. The experimental
protocols were approved by the Ethical Committee of
Cairo University.
NDEA as carcinogenic material and the flavonoid querce-
tin, enzymes and coenzymes were obtained from Sigma-
Aldrich Co. (St. Louis, Missouri, USA). Other chemicals
were from Analar grade. NDEA was dissolved in saline (8
mg/1 ml vehicle). Quercetin was suspended in 0.5% car-
boxymethyl cellulose (20 mg/1 ml vehicle).
Induction of liver carcinogenesis
Induction of liver carcinogenesis was carried out accord-
ing the following protocol: each rat received an oral dose
of 20 mg/kg (NDEA/weight), for 9 weeks (5 days/week)
followed by another oral dose of 10 mg/kg (NDEA/
weight) for 6 weeks (5 days/week).
Experimental groups
Rats were acclimatized for 4 days before carrying out the
experimental work. Animals were divided into 3 groups:
the 1st group (14 animals) was treated with NDEA for 15
weeks as detailed above and designated as (NDEA-
treated), the 2nd group (12 animals) was treated simulta-
neously with NDEA (20 mg/kg for 9 weeks followed by 10
mg/kg for 6 weeks) and Quercetin in a dose of 200 mg/kg
daily, for 15 weeks as detailed above, the 3rd group of rats
(10 animals) was used as control (oral dose of saline was
administered). At the end of the experimental period, rats
were food-deprived overnight and were killed by cervical
decapitation. The liver was immediately excised, rinsed
with ice-cold saline and blotted dry and accuratelyJournal of Experimental & Clinical Cancer Research 2009, 28:80 http://www.jeccr.com/content/28/1/80
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weighed. A small portion of liver was fixed in 10% formal-
saline for the histopathological studies.
DNA extraction and amplification of RAPD markers
Genomic DNA was extracted from liver samples using
Wizard Genomic DNA Purification kit (Promega, Madi-
son, USA) following the manufacturer's instructions.
DNA was visualized on a 0.7% agarose gel. Quality and
concentration of DNA were determined spectrophoto-
metrically. Three random primers were used to study the
genetic difference between the examined animals. The
primers used in this study are listed in Table 1. Optimiza-
tion of PCR conditions for ultimate discriminatory power
was achieved. RAPD-PCR was carried out in a 25 μl total
reaction volume containing 2.5 μl 10× buffer, 0.2 mM
dNT'Ps, 100 pmol primer, 2 U Taq DNA polymerase, 3.0
mM MgCl2, 50 ng DNA template and nuclease-free water.
The amplification program used was 4 min at 94°C (hot
start), 1 min at 94°C, 1 min at 30°C and 1 min at 72°C
for 36 cycles followed by one cycle of 72°C for 10 min.
PCR amplification was carried out in a DNA thermal
cycler (Model 380 A, Applied Biosystems, CA, USA). PCR
products were visualized on 2% agarose gel.
Specific PCR assay for polymorphism of p53 gene
For the p53 PCR, DNA of control, hepatic carcinoma and
quercetin-treated samples was used up for the p53-specific
PCR assays. A primer set (Forward: 5'-CAT CGA ATT CTG
GAA ACT TTC CAC TTG AT-3' and Reverse: 5'-GTA GGA
ATT CGT CCC AAG CAA TGG ATG AT-3') was used for
detection of p53 sequence. The PCR conditions were as
follows: denaturation at 94°C for 5 minutes, then 35
cycles with denaturation at 94°C for 1 minute, annealing
at 48°C for 1 minutes and elongation at 72°C for 1
minute. In the last cycle, the elongation step was extended
to 10 minutes. PCR product (300 bp) was separated in 2%
agarose gel.
Oxidant/antioxidant status of liver tissue
Accurately weighed pieces of liver tissue were treated dif-
ferently to study the oxidant/antioxidant status of the
liver. Two portions were used to prepare 10% homoge-
nate in 1.15% KCl and 5% homogenate in 3% sulfosali-
cylic acid, centrifuged at 1000 ×g at 4°C for 20 minutes.
Resulted supernatants were used for the assay of malond-
ialdehyde (MDA) as described by Yoshioka et al. [20] and
glutathione (GSH) according to Srivastava and Beutler
[21] levels, respectively. Portion of the liver was homoge-
nized in Tris-sucrose buffer pH 7.4 (10% homogenate)
and centrifuged at 15,000 ×g, at 4°C for 30 minutes, using
Dupont-Sorvall Ultracentrifuge (USA), to isolate the
cytosolic fraction. Cytosolic fraction was used for glutath-
ione peroxidase (GPX) assay as described by Arthur and
Boyne [22] and glutathione reductase (GR) according to
Long and Carson [23]. Protein concentration of the above
supernatant was estimated by the method of Lowry et al.
[24].
Histopathological examination of liver sections of the 
different groups
Slices of liver tissue were fixed in formal-saline, dehy-
drated in alcohol series and embedded in paraffin wax.
Serial sections were made from each paraffin block,
stained by eosin and hematoxlin dyes, and then submit-
ted to histopathological examination under light micro-
scope (Olympus Optical Corp., Tokyo, Japan).
Statistical analyses
RAPD-PCR banding patterns of the liver samples were
scored for the presence (1) or for absence (0) of each
amplified band. All RAPD assays were repeated thrice and
only the reproducible bands were scored. For considering
a marker as polymorphic, the absence of an amplified
product in at least one sample was used as a criterion. For
genetic distance analysis, data sets were fed into the clus-
tering program of SPSS (Version 14.0) and similarity
matrix was determined using Jaccard's coefficient. Next,
distance matrix (distance = 1 - similarity) was calculated.
Based on similarity matrices using the unweighted pair
group method analysis, STATISTICA program for Win-
dows, 1995 (StatSoft, Inc., USA) was used to generate
UPGMA dendrogram [25]. The Chi-square test was used
to analyze the data obtained. Results of oxidant/antioxi-
dant status were analyzed using one way analysis of vari-
ance (ANOVA) followed by Kruskal-Wallis test using SPSS
software (Ver. 14.0). Differences were considered statisti-
cally significant if P < 0.05.
Results
RAPD analysis
RAPD analysis of liver samples was carried out using four
different primers. The results revealed that approximately
37 different banding patterns were obtained. Amplifica-
tion with EZ primer generated 3 monomorphic bands and
6 polymorphic bands in a total of 9-banded RAPD pat-
terns (Fig. 1). P53 forward and reverse primers generated
the same banding pattern: 2 monomorphic bands and 5
polymorphic bands in a total of 7-banded RAPD patterns.
Table 1: Arbitrary primer sequences used in this study
Primer name Primer sequence
EZ 5'-GCATCACAGACCTGTTATTGCCTC-3'
Chi15 5'-GGYGGYTGGAATGARGG-3'
P53 F 5'-CATCGAATTCTGGAAACTTTCCACTTGAT-3'
P53 R 5'GTAGGAATTCGTCCCAAGCAATGGATGAT-3'Journal of Experimental & Clinical Cancer Research 2009, 28:80 http://www.jeccr.com/content/28/1/80
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Whenever,  Chi15  primer generated one monomorphic
band and 6 polymorphic bands in a total of 7-banded
RAPD patterns (Fig. 1). A total of 30 distinct bands
obtained were used for cluster analysis. The UPGMA den-
drogram revealed that 80% similarity cut-off value gave
two major clusters (RAPD genotypes: HC: NDEA-treated,
Q_T: NDEA+Q group and CON: Control). NDEA+Q and
control groups clustered in the same genotype while the
NDEA-treated samples clustered in a separate genotype
(Fig. 2). Chi square and Fisher's tests revealed that signifi-
cant differences between both control and NDEA-treated
and between NDEA-treated and NDEA+Q groups. How-
ever no significant difference between control and
NDEA+Q groups was observed in case of primer P53.
Specific PCR assay for polymorphism of p53 gene
Two oligonucleotide primers were designed to amplify
300 bp within the open reading frame (orf) of p53 gene and
were successfully used in PCR. PCR analysis of liver sam-
ples revealed a uniform pattern of allele separation in
both control and NDEA+Q samples emphasizing the
same results obtained by RAPD-PCR analysis (Fig. 3, lanes
1, 8 and 9). These results confirmed the preventive effect
of the flavonoid quercetin on hepatocarcinoma in rats
(Figs. 2 and 3).
Oxidant/antioxidant status of liver tissue
The data presented in Table 2 show the oxidative stress
(MDA concentration) and antioxidant activity (GSH, GR
and GPX concentrations) of control, NDEA-treated and
NDEA+Q treated liver tissues. MDA was studied as oxida-
tive stress parameter while GSH, GR and GPX were esti-
mated as indicators for antioxidant activity. Lipid
peroxidation represented in MDA concentration showed
significant increase (P < 0.001) in case of NDEA-treated
rats in comparison to control (about 1.6 folds of control
value). Treatment with quercetin (NDEA+Q) resulted in
approximately normalization of MDA concentration
(Table 2). Hepatic GSH content increased significantly (P
< 0.01) in cases of both NDEA-treated and NDEA+Q
group of rats in comparison to control group. Although
treatment with quercetin (NDEA+Q) resulted in a signifi-
cant decrease (P < 0.05) of hepatic GSH when compared
to NDEA-treated rats, it still significantly higher (P < 0.01)
than control GSH level (Table 2). NDEA-treated group
exhibited significant increase (P < 0.01) in GR and GPX
activities when compared to the control group. Treatment
with quercetin (NDEA+Q) resulted in approximately nor-
malization of GR and GPX activities, based on non-signif-
icant difference between NDEA+Q and control groups
(Table 2).
Representative 2% agarose gels of RAPD-PCR patterns generated from 10 liver samples using three arbitrary primers: EZ: left,  Chi15: middle and P53 F: right Figure 1
Representative 2% agarose gels of RAPD-PCR patterns generated from 10 liver samples using three arbitrary 
primers: EZ: left, Chi15: middle and P53 F: right. Lane M: DNA marker 1 kb Ladder, lane 1: control animal, lanes 2–5: 
NDEA-treated animals and lanes 6–10: NDEA+Q-treated animals.Journal of Experimental & Clinical Cancer Research 2009, 28:80 http://www.jeccr.com/content/28/1/80
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Histopathological examination
Hepatic histopathological features of control, NDEA-
treated and NDEA+Q rats were illustrated in Fig. (4). Nor-
mal liver tissue showed hepatic lobule with normal archi-
tecture (Fig. 4a). Hepatic lobules were normal, each
lobule consisted of normal hepatocytes arranged in
hepatic strands, normal hepatic vein and each lobule con-
tained blood vessels and bile ducts (Fig. 4a). No lipid
droplets have been observed in the hepatocytic cyto-
plasm. No signs of blood congestion in blood vessels have
been observed throughout the sections (Fig. 4a). Liver tis-
sue of the NDEA-treated rats showed pleomorphism of
nuclei, some cells exhibit multiple nucleoli (encircled),
others are pyknotic (Pyk), some cells possess intranuclear
vacuole (IV), some showed cytoplasmic vacuoles (V) and
cellular infiltration (Inf) (Fig. 4b). Massive area of vacu-
olated hepatocytes (VH), cellular infiltration (Inf) and
pyknotic nuclei were shown in Fig. (4c). Vacuolated cyto-
plasm (V), hyperchromatic nuclei (HC), pyknotic nuclei
(Pyk) and numerous Kupffer cells (K) were seen in Fig.
(4d). Hyperchromatic malignant nuclei (HCM) were
exhibited in Fig. (4e). Liver tissue of the quercetin
(NDEA+Q) treated rats showed normal hepatic lobule
architecture (normal hepatocytes, hepatic vein, nuclei and
blood vessels). Some bile droplets were observed in Fig.
(4f). Fig. (4g) showed normal hepatocytes, hepatic vein,
nuclei, bile ducts and blood vessels.
Discussion
Hepatocellular carcinoma is the most frequent hepatic
primary neoplasm. Its geographic distribution is inhomo-
geneous, with high, medium and low zones of incidence
[26].
In the present study, RAPD, cluster and statistical analyses
indicated the closer relation between control and
NDEA+Q samples. Meanwhile, NDEA-treated samples
were clustered in a separate group. These results were sub-
sequently confirmed by specific PCR assay for polymor-
phism of P53 gene which revealed a uniform pattern of
A dendrogram constructed on the basis of similarity index among liver samples using the three RAPD primers Figure 2
A dendrogram constructed on the basis of similarity index among liver samples using the three RAPD prim-
ers. CON: control, Q_T: NDEA+Q-treated and HC: NDEA-treated animals.Journal of Experimental & Clinical Cancer Research 2009, 28:80 http://www.jeccr.com/content/28/1/80
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allele separation in both control and NDEA+Q samples.
To investigate how quercetin exerted its anticancer effect,
oxidant/antioxidant status was tested. NDEA-treated sam-
ples exhibited allover higher oxidant/antioxidant status
than control and NDEA+Q samples. Quercetin
(NDEA+Q) succeeded in most cases to normalize the oxi-
dant/antioxidant status of NDEA-treated samples. Moreo-
ver, histopathological confirmation showed normal liver
histology of the NDEA+Q samples. Our results are agree-
able with Lijinsky [4] and Bogovski and Bogovski, [7] who
reported that NDEA is known as precarcinogen capable of
inducing tumors in different animal species and are sus-
pected of being involved in some human tumors [7]. Con-
firming results reported that administration of NDEA to
rats resulted in lipid peroxidation (represented in higher
MDA levels) and enhanced chemiluminescence in liver
preneoplastic nodules, indicating the formation of acti-
vated oxygen species [27]. NDEA also produces 8-hydrox-
yguanine (8-OHG) [28], an indicator of oxidative damage
to DNA (P53 results) and the most abundant of more than
20 types of modifications produced under conditions of
oxidative stress. This premutagenic DNA damage results
in specific types of mutations and is likely to be involved
in carcinogenesis. In contrast, Andrzejewski et al. [8] pos-
tulated that NDEA is an epigenetic chemical compound.
The antitumor effects of plant flavonoids have been
reported to induce cell growth inhibition and apoptosis in
a variety of cancer cells [9]. Quercetin, a ubiquitous bioac-
tive flavonoid, can inhibit the proliferation of cancer cells
[10,11]. It has been shown that quercetin treatment
caused cell cycle arrests such as G2/M arrest or G1 arrest in
different cell types [10,29]. Moreover, quercetin-mediated
apoptosis may result from the induction of stress proteins,
disruption of microtubules and mitochondrial, release of
cytochrome  c, and activation of caspases [11,30]. Gra-
nado-Serrano et al. [31] reported that quercetin may be a
potential chemopreventive or therapeutic agent in hepa-
tocarcinoma cells and further efforts to investigate these
possibilities are needed. Specific P53 gene PCR results may
be contributed to the quercetin-mediated down regula-
tion of mutant P53 as reported by Avila et al. [32]. Contra-
dictory results were reported by Chaumontet et al. [33]
who reported the lack of tumor-promoting effects of the
flavonoids. The oxidant/antioxidant status of liver sam-
ples illustrated that quercetin exerted its preventive effect
through inhibition of lipid peroxidation to prevent oxida-
tive DNA damage [28]. Consequently, the levels of GSH
(a key player in reduction and detoxification processes)
[17], GR (reduces GSSG to GSH which is an important cel-
lular antioxidant) [18,19] and GPX (whose main biologi-
cal role is to protect the organism from oxidative damage)
[18,19] decreased significantly in NDEA+Q group. The
higher concentration of GSH in NDEA+Q treated group
PCR amplification of p53 exon from liver tissues Figure 3
PCR amplification of p53 exon from liver tissues. Lane 
M: DNA marker, lane 1: control, lanes 2–4 NDEA-treated 
animals and lanes 8–9: NDEA+Q-treated animals.
Table 2: Effect of quercetin treatment on liver oxidant/antioxidant biomarkers in NDEA-induced liver carcinogenesis in rats
Parameter Control NDEA-Treated group NDEA+Q group
MDA
nmol/g liver
55.6 ± 3.41 90.4 ± 8.01a 60.8 ± 3.30b
GSH
mg/g liver
1.5 ± 0.104 3.82 ± 0.149a 3.26 ± 0.088ab
GR nmol/mg protein/min 80.1 ± 2.53 101 ± 5.95a 83.6 ± 2.30b
GPX nmol/mg protein/min 324.36 ± 7.6 397.2 ± 13.16a 315.6 ± 6.09b
a. Significantly different from control.
b. Significantly different from NDEA-administered rats.Journal of Experimental & Clinical Cancer Research 2009, 28:80 http://www.jeccr.com/content/28/1/80
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than control could be attributed to the increase of GSSG-
GSH transformation, by GR enzyme, to overcome the
increased lipid peroxidation exerted by NDEA. Inhibitory
hitopathological effect of quercetin looks like that
reported in cyclo-oxygenase and phospholipase A2 inhib-
itors [34].
Conclusively, this paper demonstrated the carcinogenic
effect of NDEA as well as the preventive effect of the flavo-
noid quercetin on hepatocarcinoma in rats by RAPD-PCR
and by tracing the effect on P53 gene. Oxidant/antioxidant
results suggested that the eventual schedule of the cell is as
follows: on treating rats with NDEA (NDEA-treated), lipid
peroxidation increases (represented in high MDA concen-
tration), GR enzyme succeeded in GSSG-GSH transforma-
tion (represented in high GSH concentration), GSH and
GPX enzyme failed to exert antioxidant effect and could
not protect organism against oxidative damage. Oxidative
damage to DNA induced specific mutations (RAPD and
P53 PCR results) and these mutations are likely involved in
carcinogenesis (histopathological evidence). In case of
NDEA+Q group, lipid peroxidation inhibited (repre-
sented in normal MDA concentration), GR enzyme suc-
ceeded in GSSG-GSH transformation (represented in high
GSH concentration), GSH and GPX enzyme exerted anti-
oxidant effects and could protect organism against oxida-
tive damage. DNA preserved its normal status (RAPD and
P53 PCR results) and hepatic lobule exhibited normal
architecture. Hereby, it was proved that the mode of
action by which quercetin exerted hepatic anticancer
effect could be interpreted via oxidant/antioxidant status
of the liver.
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